NASDAQ, TSX: NVCN
VANCOUVER, July 16, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that, in connection with its new final short form base shelf prospectus (the "Base Shelf Prospectus") filed with securities regulatory authorities in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario (the "Provinces") and its corresponding shelf registration statement on Form F-10 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") under the U.S./Canada Multijurisdictional Disclosure System, which were filed to replace its prior expiring base shelf prospectus and related registration statement, the Company has filed a prospectus supplement (the "Prospectus Supplement") with the securities regulatory authorities in the Provinces and with the SEC covering the issuance, from time to time, of units, warrants and common shares of the Company underlying the outstanding warrants previously issued pursuant to the Company's underwritten public offering of 6,609,588 Series A units of the Company and 19,066,780 Series B units of the Company at a price of $1.46 per unit, which closed on November 17, 2017. This "administrative" filing effectively moves the registration of these underlying units, warrants and common shares from the Company's prior registration statement, which expired on July 9, 2018, to the new Registration Statement. It does not involve a new financing.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
A copy of the Registration Statement, including the related prospectus, or the Prospectus Supplement may be obtained by submitting a request to Chris Clark, Chief Financial Officer, at Neovasc's address at 5138-13562 Maycrest Way, Richmond, British Columbia, Canada, V6V 2J7. Copies of the Base Shelf Prospectus and Prospectus Supplement are available on SEDAR at www.sedar.com. Copies of the Registration Statement can be found on the SEC website at www.sec.gov.
About Neovasc Inc. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc ReducerTM (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the TiaraTM (the "Tiara"), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe.
VANCOUVER, July 16, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that, in connection with its new final short form base shelf prospectus (the "Base Shelf Prospectus") filed with securities regulatory authorities in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario (the "Provinces") and its corresponding shelf registration statement on Form F-10 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") under the U.S./Canada Multijurisdictional Disclosure System, which were filed to replace its prior expiring base shelf prospectus and related registration statement, the Company has filed a prospectus supplement (the "Prospectus Supplement") with the securities regulatory authorities in the Provinces and with the SEC covering the issuance, from time to time, of units, warrants and common shares of the Company underlying the outstanding warrants previously issued pursuant to the Company's underwritten public offering of 6,609,588 Series A units of the Company and 19,066,780 Series B units of the Company at a price of $1.46 per unit, which closed on November 17, 2017. This "administrative" filing effectively moves the registration of these underlying units, warrants and common shares from the Company's prior registration statement, which expired on July 9, 2018, to the new Registration Statement. It does not involve a new financing.
Advertisement
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Advertisement
A copy of the Registration Statement, including the related prospectus, or the Prospectus Supplement may be obtained by submitting a request to Chris Clark, Chief Financial Officer, at Neovasc's address at 5138-13562 Maycrest Way, Richmond, British Columbia, Canada, V6V 2J7. Copies of the Base Shelf Prospectus and Prospectus Supplement are available on SEDAR at www.sedar.com. Copies of the Registration Statement can be found on the SEC website at www.sec.gov.
About Neovasc Inc. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc ReducerTM (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the TiaraTM (the "Tiara"), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe.
View original content:http://www.prnewswire.com/news-releases/neovasc-announces-filing-of-administrative-prospectus-supplement-relating-to-expiry-of-prior-shelf-prospectus--registration-statement-300680996.html
SOURCE Neovasc Inc.
